NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

Some drugs that have gained approval this year so far include AstraZeneca’s Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) (to treat neurogenic orthostatic hypotension), BioMarin’s Vimizim (Morquio A syndrome) and Vanda Pharma’s Hetlioz. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -5.75% in last session and finished the day at $4.92. Traded volume was 3.02million shares in … Continue reading NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

John Meady04/1404/14

Biotech Stocks Touched New Lows: Onconova Therapeutics Inc (NASDAQ:ONTX), Array Biopharma (NASDAQ:ARRY), AVEO Pharmaceuticals (NASDAQ:AVEO), Infinity Pharmaceuticals (NASDAQ:INFI)

Onconova Therapeutics Inc (NASDAQ:ONTX)’s share price has entered into oversold territory with an RSI value of 19.3. The Zacks Consensus Estimate for Onconova Therapeutics Inc (NASDAQ:ONTX) for the full year period has improved 75 cents over the past two months to $-2.09 per share. Currently, Onconova Therapeutics Inc (NASDAQ:ONTX) has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get … Continue reading Biotech Stocks Touched New Lows: Onconova Therapeutics Inc (NASDAQ:ONTX), Array Biopharma (NASDAQ:ARRY), AVEO Pharmaceuticals (NASDAQ:AVEO), Infinity Pharmaceuticals (NASDAQ:INFI)

Mark Doerr04/0704/07

Investors Should Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Comcast Corporation (NASDAQ:CMCSA), Tech Data Corp. (NASDAQ:TECD), Worthington Industries, Inc. (NYSE:WOR), LDR Holding Corporation (NASDAQ:LDRH)

On Dec 12, Oncothyreon Inc. announced that Array BioPharma, Inc. (NASDAQ:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380. Array BioPharma, Inc. (NASDAQ:ARRY) belongs to Healthcare sector. Its weekly performance is … Continue reading Investors Should Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Comcast Corporation (NASDAQ:CMCSA), Tech Data Corp. (NASDAQ:TECD), Worthington Industries, Inc. (NYSE:WOR), LDR Holding Corporation (NASDAQ:LDRH)

Chris Lewis12/1812/18

Why Need to Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Hewlett-Packard Company (NYSE:HPQ), Polycom, Inc. (NASDAQ:PLCM), Endurance International Group (NASDAQ:EIGI), Diamond Offshore Drilling (NYSE:DO)

Array BioPharma, Inc. (NASDAQ:ARRY) announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory … Continue reading Why Need to Watch: Array BioPharma, Inc. (NASDAQ:ARRY), Hewlett-Packard Company (NYSE:HPQ), Polycom, Inc. (NASDAQ:PLCM), Endurance International Group (NASDAQ:EIGI), Diamond Offshore Drilling (NYSE:DO)

Adam Keintzel12/0412/04

Today’s Watch List: Array BioPharma, Inc. (NASDAQ:ARRY), Fairchild Semiconductor International Inc. (NASDAQ:FCS), Flowserve Corp. (NYSE:FLS), Red Hat, Inc. (NYSE:RHT), JBSS

Array Biopharma (NASDAQ:ARRY) released its earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.22) by $0.01. The company had revenue of $6.07 million for the quarter, compared to the consensus estimate of $6.35 million. During the same quarter in the prior year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was … Continue reading Today’s Watch List: Array BioPharma, Inc. (NASDAQ:ARRY), Fairchild Semiconductor International Inc. (NASDAQ:FCS), Flowserve Corp. (NYSE:FLS), Red Hat, Inc. (NYSE:RHT), JBSS

Adam Keintzel11/0611/06

Shining on Major News : ProQR Therapeutics (NASDAQ:PRQR), Array BioPharma (NASDAQ:ARRY), Brooks Automation (NASDAQ:BRKS), Taubman Centers, Inc. (NYSE:TCO),GERN

ProQR Therapeutics N.V. (NASDAQ:PRQR) announced today the closing of its initial public offering of 8,625,000 ordinary shares at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,125,000 additional ordinary shares. The aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $102 … Continue reading Shining on Major News : ProQR Therapeutics (NASDAQ:PRQR), Array BioPharma (NASDAQ:ARRY), Brooks Automation (NASDAQ:BRKS), Taubman Centers, Inc. (NYSE:TCO),GERN

Kevin Long10/0810/08